Tavapadon (Juvmo) is a new once-daily pill for Parkinson’s motor symptoms. Here’s how it works, who it may help and what to ...
Juvmo was designed to offer a reduction in motor symptoms, while reducing non-motor side effects, through its more selective ...
The Brighterside of News on MSN
Long-term air pollution exposure linked to Parkinson’s disease risk
A Cambridge review links long-term particle pollution with increased Parkinson’s risk while highlighting major research gaps.
Although a clinical setback last year continues to loom in the background, AbbVie’s $8.7 billion bet on Cerevel Therapeutics ...
AbbVie stock (ABBV) slipped slightly on Monday, down 0.29%, after the company announced a major regulatory win. The FDA ...
Health and Me on MSN
FDA approves new Parkinson’s drug that targets dopamine receptors: All about Tavapadon
The US Food and Drug Administration recently approved a new drug for Parkinson's disease that works by stimulating dopamine receptors.
JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease1 Taken once daily with or without levodopa therapy, JUVMO offers patients ...
2d
AskBio’s bold ambition to help people with Parkinson’s disease look forward — and maybe even tango
"Among the aims of the research team is to better understand whether gene therapy may one day provide a different approach to ...
The FDA approved AbbVie’s once-daily oral drug Juvmo (tavapadon) for adults with Parkinson’s disease. Phase 3 trials found ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results